Craniofacial morphology in Turner syndrome patientstreated with growth hormone

Jovana Juloski; Ivana Scepan; Neda Stefanovic; Tina Pajevic; Evgenija Markovic; Branislav Glisic

doi:10.5937/sejodr2-15242

Jovana Juloski University of Belgrade, School of Dental Medicine, Department of Orthodontics
Ivana Scepan University of Belgrade, School of Dental Medicine, Department of Orthodontics
Neda Stefanovic University of Belgrade, School of Dental Medicine, Department of Orthodontics
Tina Pajevic University of Belgrade, School of Dental Medicine, Department of Orthodontics
Evgenija Markovic University of Belgrade, School of Dental Medicine, Department of Orthodontics
Branislav Glisic University of Belgrade, School of Dental Medicine, Department of Orthodontics

DOI: https://doi.org/10.5937/sejodr2-15242

Abstract

Introduction: In addition to well-established physical characteristics, Turner syndrome patients have distinct craniofacial morphology.Since short stature is the most typical characteristic, Turner syndrome patients are commonly treated with growth hormone in orderto increase final height. At the same time, growth hormone treatment was found to influence craniofacial growth and morphologyin various groups of treated patients. Whereas craniofacial characteristics of Turner syndrome patients are well documented,comparatively little is known of craniofacial morphology of those who are treated with growth hormone.

Aim: The aim of this study was to investigate craniofacial morphology in Turner syndrome patients treated with growth hormone incomparison to healthy females.

Materials and methods: The cephalometric evaluation was conducted on twenty lateral cephalograms of Turner syndrome patients(13.53 ± 4.04 years) treated with growth hormone for at least one year (4.94 ± 1.92 years in average). As a control group, fortylateral cephalograms of healthy female controls, who matched Turner syndrome patients by chronological (11.80 ± 2.37 years) and skeletal age, were used. Eleven angular, seven linear measurements and six dimensional ratios were measured to describe craniofacial morphology.

Results: The results obtained for angular measurements, in cephalometric analyses for Turner syndrome patients treated with growth hormone, revealed bimaxillary retrognathism. The linear measurements indicated longer mandibular ramus, anterior cranial baseand both anterior and posterior facial heights. However, ranial base and maxilla were in proportion to the anteriorcranial base, when comparing dimensional ratios. Anterior cranial base, maxilla and mandibular ramus were larger in proportion tomandibular body; as well as posterior facial height was when compared to anterior facial height.Turner syndrome patients treated with growth hormone expressed distinct craniofacial morphology compared to controls. Apart from retrognathic maxilla and mandible, they exhibited over developed mandibular ramus height and elongated facial heights.

Conclusions: The results from this study have shown that Turner syndrome patients treated with growth hormone expressed distinct craniofacial morphology compared to controls. These differences include retrognathic maxilla and mandible, over developed mandibular ramus height and elongated facial heights. This specific craniofacial morphology was formed under combined influenceof X chromosome deficiency and growth hormone therapy.

References

Ranke MB, Saenger P. Turner’s syndrome. Lancet. 2001;358(9278):309-14.

Rongen-Westerlaken C, vd Born E, Prahl-Andersen B, Rikken B, Teunenbroek V, Kamminga N, et al. Shape of the craniofacial complex in children with Turner syndrome. J Biol Buccale. 1992;20(4):185-90.

Midtbo M, Wisth PJ, Halse A. Craniofacial morphology in young patients with Turner syndrome. Eur J Orthod. 1996;18(3):215-25.

Babic M, Glisic B, Scepan I. Mandibular growth pattern in Turner’s syndrome. Eur J Orthod. 1997;19(2):161-4.

Gron M, Pietila K, Alvesalo L. The craniofacial complex in 45,X/46,XX females. Arch Oral Biol. 1999;44(12):1077-84.

Perkiomaki MR, Kyrkanides S, Niinimaa A, Alvesalo L. The relationship of distinct craniofacial features between Turner syndrome females and their parents. Eur J Orthod. 2005;27(1):48-52.

Dumancic J, Kaic Z, Varga ML, Lauc T, Dumic M, Milosevic SA, et al. Characteristics of the craniofacial complex in Turner syndrome. Arch Oral Biol. 2010;55(1):81-8.

Babić M, Sćepan I, Mićić M. Comparative cephalometric analysis in patients with X-chromosome aneuploidy. Arch Oral Biol. 1993;38(2):179-83.

Alvesalo L. Human sex chromosomes in oral and craniofacial growth. Arch Oral Biol. 2009;54 Suppl 1:S18-24.

Oliveira CS, Alves C. The role of the SHOX gene in the pathophysiology of Turner syndrome. Endocrinol Nutr. 2011;58(8):433-42.

Gravholt CH. Epidemiological, endocrine and metabolic features in Turner syndrome. Eur J Endocrinol. 2004;151(6):657-87.

Kirk J. Indications for growth hormone therapy in children. Arch Dis Child. 2012;97(1):63-8.

Saenger P, Wikland KA, Conway GS, Davenport M, Gravholt CH, Hintz R, et al. Recommendations for the diagnosis and management of Turner syndrome. J Clin Endocrinol Metab. 2001;86(7):3061-9.

Ross J, Lee PA, Gut R, Germak J. Impact of age and duration of growth hormone therapy in children with Turner syndrome. Horm Res Paediatr. 2011;76(6):392-9.

Sas TC, de Muinck Keizer-Schrama SM, Stijnen T, Jansen M, Otten BJ, Gera Hoorweg-Nijman JJ, et al. Normalization of height in girls with Turner syndrome after long-term growth hormone treatment: results of a randomized dose-response trial. J Clin Endocrinol Metab. 1999;84(12):4607-12.

Litsas G. Growth hormone therapy and craniofacial bones: a comprehensive review. Oral Dis. 2013;19(6):559-67.

Cantu G, Buschang PH, Gonzalez JL. Differential growth and maturation in idiopathic growth-hormone-deficient children. Eur J Orthod. 1997;19(2):131-9.

Kjellberg H, Wikland KA. A longitudinal study of craniofacial growth in idiopathic short stature and growth hormone-deficient boys treated with growth hormone. Eur J Orthod. 2007;29(3):243-50.

Funatsu M, Sato K, Mitani H. Effects of growth hormone on craniofacial growth. Angle Orthod. 2006;76(6):970-7.

Forsberg CM, Krekmanova L, Dahllof G. The effect of growth hormone therapy on mandibular and cranial base development in children treated with total body irradiation. Eur J Orthod. 2002;24(3):285-92.

Van Erum R, Mulier M, Carels C, Verbeke G, de Zegher F. Craniofacial growth in short children born small for gestational age: effect of growth hormone treatment. J Dent Res. 1997;76(9):1579-86.

Van Erum R, Carels C, Verbeke G, de Zegher F. Craniofacial growth in short children born small for gestational age: two years follow-up after high-dose growth hormone treatment. J Craniofac Genet Dev Biol. 1997;17(4):184-9.

Poole AE, Greene IM, Buschang PH. The effect of growth hormone therapy on longitudinal growth of the oral facial structures in children. Prog Clin Biol Res. 1982;101:499-516.

Rongen-Westerlaken C, vd Born E, Prahl-Andersen B, von Teunenbroek A, Manesse P, Otten BJ, et al. Effect of growth hormone treatment on craniofacial growth in Turner’s syndrome. Acta Paediatr. 1993;82(4):364-8.

Hass AD, Simmons KE, Davenport ML, Proffit WR. The effect of growth hormone on craniofacial growth and dental maturation in Turner syndrome. Angle Orthod. 2001;71(1):50-9.

Simmons KE. Growth hormone and craniofacial changes: preliminary data from studies in Turner’s syndrome. Pediatrics. 1999;104(4 Pt 2):1021-4.

Van Erum R, Mulier G, Carels C, de Zegher F. Craniofacial growth and dental maturation in short children born small for gestational age: effect of growth hormone treatment. Horm Res. 1998;50(3):141-6.

Rizell S, Barrenas ML, Andlin-Sobocki A, Stecksen-Blicks C, Kjellberg H. 45,X/46,XX karyotype mitigates the aberrant craniofacial morphology in Turner syndrome. Eur J Orthod. 2013;35(4):467-74.

Djordjević VA, Jovanović JV, Pavković-Lučić SB, Drakulić DD, Djurović MM, Gotić MD. Cytogenetic findings in Serbian patients with Turner’s syndrome stigmata. Genet Mol Res. 2010;9(4):2213-21.

Andersen E, Sonnesen L, Kjaer MS, Fischer Hansen B, Kjaer I. The prenatal cranial base complex and hand in Turner syndrome. Eur J Orthod. 2000;22(2):185-94.

Juloski J, Glisic B, Scepan I, Milasin J, Mitrovic K, Babic M. Ontogenetic changes of craniofacial complex in Turner syndrome patients treated with growth hormone. Clin Oral Investig. 2013;17(6):1563-71.

Solem RC, Eames BF, Tokita M, Schneider RA. Mesenchymal and mechanical mechanisms of secondary cartilage induction. Dev Biol. 2011;356(1):28-39.